JP Morgan Chase’s Translate Bio, Inc. Common Stock TBIO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2021
Q3 | – | Sell |
-1,480,611
| Closed | -$40.8M | – | 7036 |
|
|
2021
Q2 | $40.8M | Buy |
1,480,611
+502,550
| +51% | +$9.88M | ﹤0.01% | 1318 |
|
|
2021
Q1 | $16.1M | Buy |
978,061
+229,933
| +31% | +$5.24M | ﹤0.01% | 1937 |
|
|
2020
Q4 | $13.8M | Buy |
748,128
+128,883
| +21% | +$2.31M | ﹤0.01% | 1936 |
|
|
2020
Q3 | $8.43M | Buy |
619,245
+352,938
| +133% | +$5.44M | ﹤0.01% | 2175 |
|
|
2020
Q2 | $4.77M | Buy |
266,307
+148,452
| +126% | +$2.24M | ﹤0.01% | 2490 |
|
|
2020
Q1 | $1.18M | Buy |
117,855
+65,218
| +124% | +$534K | ﹤0.01% | 3305 |
|
|
2019
Q4 | $429K | Buy |
52,637
+41,818
| +387% | +$386K | ﹤0.01% | 4315 |
|
|
2019
Q3 | $107K | Buy |
10,819
+2,751
| +34% | +$26K | ﹤0.01% | 4879 |
|
|
2019
Q2 | $104K | Buy |
8,068
+893
| +12% | +$9.41K | ﹤0.01% | 4920 |
|
|
2019
Q1 | $73K | Buy |
7,175
+4,670
| +186% | +$35.8K | ﹤0.01% | 4996 |
|
|
2018
Q4 | $19K | Buy |
2,505
+234
| +10% | +$1.71K | ﹤0.01% | 5342 |
|
|
2018
Q3 | $23K | Buy |
+2,271
| New | +$26.4K | ﹤0.01% | 5398 |
|
JP Morgan Chase's TBIO Position: Q3 2021 in Review
JP Morgan Chase sold out of Translate Bio, Inc. Common Stock (TBIO) in Q3 2021, closing a stake of 1,480,611 shares — an estimated $40.8M sold.
JP Morgan Chase first reported a position in TBIO in Q3 2018 and held it in 12 quarters. The position peaked at $40.8M in Q2 2021. 0 funds tracked by Wall St. Rank hold TBIO as of Q3 2021.
- JP Morgan Chase reported no remaining Translate Bio, Inc. Common Stock position as of Q3 2021 after selling out during the quarter.
- JP Morgan Chase sold 1,480,611 Translate Bio, Inc. Common Stock shares in Q3 2021, an estimated $40.8M.
- JP Morgan Chase first reported a position in Translate Bio, Inc. Common Stock in Q3 2018 and held it in 12 quarters.
- JP Morgan Chase's Translate Bio, Inc. Common Stock position peaked at $40.8M in Q2 2021.
- 0 funds tracked by Wall St. Rank held Translate Bio, Inc. Common Stock as of Q3 2021.
Based on JP Morgan Chase's 13F filing for Q3 2021, filed 12 Nov 2021.